文拉法辛缓释片联合阿立哌唑治疗躯体化障碍的疗效及安全性

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (385 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the venlafaxine combined with aripiprazole tablets and safety of treatment of somatization disorder. Methods Seventy-eight patients were randomly divided into treatment group (venlafaxine combined with aripiprazole tablets) and control group (venlafaxine alone), 39 cases each. In the ends of 2, 4, 6 weeks, the self-assessment lists of symptom (SCL-90) and adverse reaction scale (treatment emergent symptom scale, TESS) were used to evaluat the curative effect and adverse reactions. Results In the ends of 4 weeks, SCL-90 scores in the treatment group were higher than those in the control group, with statistically significant difference (P<0.05). TESS scores in the treatment group were significantly higher than those in the control group (P<0.05). 8 weeks, 12 weeks in the treatment group somatization, depression, anxiety and other factor scores improved significantly compared with the control group, the difference was statistically significant (P<0.05). Treatment group was 92.31%, higher than 79.49%, the difference was statistically significant (P<0.05); treatment group TESS score was 2.33?1.06, the control group was 2.12?0.96, the difference was not statistically significant (t=0.81). Conclusions Venlafaxine combined with aripiprazole tablets for treatment of somatization disorder is better than venlafaxine alone, and has good compliance.

Key words： somatization disorder venlafaxine aripiprazole

Received: 16 October 2013

ZTFLH:

R749.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Ying
	CAO Lei
	ZHOU Lei
	LIU Bai-Chuan

Cite this article:

ZHANG Ying,CAO Lei,ZHOU Lei等. Venlafaxine combined with aripiprazole tablets in treatment of somatization disorder[J]. , 2014, 25(4): 344-345.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2014/V25/I4/344

	王东林,吴彩云,吴爱勤.躯体形式障碍[J]. 医学综述,1997,3(10):471-474.
[2]	Ladwig K H,Marten M B, Erazo N,et al. Identifying somatization disorder in a population based health exam in ation survey: psychosocial burden and genderd if ferences[J]. Psychosomatics, 2001, 42(6):511-518.
[2]	Ladwig K H,Marten M B, Erazo N,et al. Identifying somatization disorder in a population based health exam in ation survey: psychosocial burden and genderd if ferences[J]. Psychosomatics, 2001, 42(6):511-518.
[3]	陈康宁,张帆,罗捷.躯体化障碍的诊疗进展[J]. 第三军医大学学报,2002,24(11):57-59.
[3]	陈康宁,张帆,罗捷.躯体化障碍的诊疗进展[J]. 第三军医大学学报,2002,24(11):57-59.
[4]	马闯胜,张淑芳,张香芝.联合小剂量抗精神病药物治疗躯体形式障碍的对照研究[J].中国民康医学杂志,2004,16(5):258-259.
[4]	马闯胜,张淑芳,张香芝.联合小剂量抗精神病药物治疗躯体形式障碍的对照研究[J].中国民康医学杂志,2004,16(5):258-259.
[5]	沈渔邨.精神病学[M].4版.北京:人民卫生出版社,2003:475-478.
[5]	沈渔邨.精神病学[M].4版.北京:人民卫生出版社,2003:475-478.
[6]	刘臣,张印.帕罗西汀对躯体形式障碍的疗效观察[J].中国实用医药,2012,11(7):171.
[6]	刘臣,张印.帕罗西汀对躯体形式障碍的疗效观察[J].中国实用医药,2012,11(7):171.
[7]	喻东山,葛茂宏. 精神科合理用药手册[M] .2版.南京:江苏科学技术出版社,2011:196-197.
[7]	喻东山,葛茂宏. 精神科合理用药手册[M] .2版.南京:江苏科学技术出版社,2011:196-197.
[8]	王刚平,颉瑞,张永录,等.帕罗西汀与文拉法辛治疗躯体化障碍的对照研究[J].山东精神医学,2006,19(4):281-282.
[8]	王刚平,颉瑞,张永录,等.帕罗西汀与文拉法辛治疗躯体化障碍的对照研究[J].山东精神医学,2006,19(4):281-282.